STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure

Valentina Cannone; Mark Ledwidge; Chris Watson; Paul M McKie; John C Burnett Jr; Kenneth McDonald

doi:10.1016/j.jacbts.2021.05.001

STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure

JACC Basic Transl Sci. 2021 Jun 16;6(6):497-504. doi: 10.1016/j.jacbts.2021.05.001. eCollection 2021 Jun.

Authors

Valentina Cannone^{1

2}, Mark Ledwidge^{3

4}, Chris Watson^{5

6}, Paul M McKie¹, John C Burnett Jr¹, Kenneth McDonald^{3

4}

Affiliations

¹ Cardiorenal Research Laboratory, Division of Circulatory Failure, Department of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota, USA.
² Department of Medicine and Surgery, University of Parma, Parma, Italy.
³ STOP-HF Unit, St Vincent's University Healthcare Group, Dublin, Ireland.
⁴ School of Medicine, University College Dublin, Dublin, Ireland.
⁵ UCD Conway Institute, School of Medicine, University College Dublin, Dublin, Ireland.
⁶ Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland.

Abstract

B-type natriuretic peptide (BNP) possesses blood-pressure-lowering, antifibrotic, and aldosterone-suppressing properties. In Stage A and B heart failure, the carriers of the minor C allele of the BNP genetic variant rs198389 have higher circulating levels of BNP and are at decreased risk of hypertension, new-onset left ventricular systolic dysfunction, and hospitalization for major adverse cardiovascular events. Future studies are warranted to investigate the role of BNP genetic testing and BNP-based therapy in the prevention of heart failure.

Keywords: B-type natriuretic peptide; BNP, B-type natriuretic peptide; HF, heart failure; LVSD, left ventricular systolic dysfunction; RAAS, renin-angiotensin-aldosterone system; SNP, single nucleotide polymorphism; STOP-HF Trial; heart failure; pGC-A, particulate guanylyl cyclase A receptor; rs198389; single nucleotide polymorphism.